Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Dosing Study of DSG3-CAART and CABA-201 in Pemphigus Vulgaris
NCT04422912Phase 2Recruiting
- Sponsor
- Cabaletta Bio
- Start
- Sep 2020
- Primary completion
- Jan 2029
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of DSG3-CAART, resecabtagene autoleucel in pemphigus vulgaris (PV), sponsored by Cabaletta Bio. Started Sep 2020; status: recruiting.
02
Drugs
DSG3-CAARTresecabtagene autoleucel
03
Conditions
pemphigus vulgaris (PV)
Beyond the preview
Go deeper on NCT04422912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04422912.